Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) is anticipated to announce its earnings results after the market closes on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Atea Pharmaceuticals Stock Performance

AVIR stock remained flat at $2.90 during midday trading on Tuesday. 517,918 shares of the company's stock were exchanged, compared to its average volume of 281,872. Atea Pharmaceuticals has a fifty-two week low of $2.75 and a fifty-two week high of $4.18. The firm has a market capitalization of $244.94 million, a P/E ratio of -1.40 and a beta of 0.19. The firm has a 50 day simple moving average of $3.17 and a two-hundred day simple moving average of $3.36.

Insider Buying and Selling

In other Atea Pharmaceuticals news, Director Franklin M. Berger sold 359,606 shares of the company's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the sale, the director now directly owns 451,897 shares of the company's stock, valued at $1,287,906.45. This represents a 44.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 17.80% of the stock is owned by insiders.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.